Advertisement
Advertisement
MIRM
Mirum Pharmaceuticals, Inc. Common Stock
81.35
USDSponsored
+0.71
+0.88%
Oct 08, 15:59 UTC -4
Closed
After-Market
80.75
-0.60
-0.74%
MIRM Earnings Reports
Positive Surprise Ratio
MIRM beat 13 of 29 last estimates.
45%
Next Report
Date of Next Report
Nov 04, 2026
Estimate for Q3 26 (Revenue/ EPS)
$182.37M
/-$0.53
Implied change from Q2 26 (Revenue/ EPS)
+3.48%
/-50.00%
Implied change from Q3 25 (Revenue/ EPS)
+37.11%
/-1160.00%
Mirum Pharmaceuticals, Inc. Common Stock earnings per share and revenue
On Aug 05, 2026, MIRM reported earnings of -1.06 USD per share (EPS) for Q2 26, missing the estimate of -0.69 USD, resulting in a -52.65% surprise. Revenue reached 176.24 million, compared to an expected 169.44 million, with a 4.01% difference. The market reacted with a -11.04% price change (close before vs. close after earnings).
Looking ahead to Q3 26, 10 analysts forecast an EPS of -0.53 USD, with revenue projected to reach 182.37 million USD, implying an decrease of -50.00% EPS, and increase of 3.48% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Nanobiotix S.A. - ADR
Report Date
Sep 25, 2026 For Q2 26
Estimate
-$0.11
Actual
-$0.70
Surprise
-496.76%
Inventiva S.A. - ADR
Report Date
Sep 28, 2026 For Q2 26
Estimate
-$0.37
Actual
-$0.25
Surprise
+33.55%
Rezolute, Inc. Common Stock (NV)
Report Date
Sep 24, 2026 For Q4 26
Estimate
-$0.15
Actual
-$0.20
Surprise
-32.45%
Palatin Technologies, Inc. Common Stock
Report Date
Sep 28, 2026 For Q4 26
Estimate
-$1.21
Actual
-$1.11
Surprise
+8.42%
NeuroSense Therapeutics Ltd. Ordinary Shares
Report Date
Sep 25, 2026 For Q2 26
Estimate
-$3.26
Actual
-$2.10
Surprise
+35.66%
FAQ
What were Mirum Pharmaceuticals, Inc. Common Stock's earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, Mirum Pharmaceuticals, Inc. Common Stock reported EPS of -$1.06, missing estimates by -52.65%, and revenue of $176.24M, 4.01% above expectations.
How did the market react to Mirum Pharmaceuticals, Inc. Common Stock's Q2 2026 earnings?
The stock price moved down -11.04%, changed from $105.79 before the earnings release to $94.11 the day after.
When is Mirum Pharmaceuticals, Inc. Common Stock expected to report next?
The next earning report is scheduled for Nov 04, 2026.
What are the forecasts for Mirum Pharmaceuticals, Inc. Common Stock's next earnings report?
Based on 10
analysts, Mirum Pharmaceuticals, Inc. Common Stock is expected to report EPS of -$0.53 and revenue of $182.37M for Q3 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.